Navigation Links
Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
Date:7/23/2009

Zdechlik was Founding member of the U.S. Clinical Molecular Diagnostic Group

NEW YORK, July 23 /PRNewswire-USNewswire/ -- Exosome Diagnostics, Inc., the developer of non-invasive molecular oncology diagnostics to aid in early cancer detection and therapeutic selection, announced today that Greg Zdechlik has been named Chief Operating Officer. As COO, Zdechlik will be responsible for driving diagnostic development, commercial relations, and product introduction including Exosome's new blood based EGFR, KRAS and BRAF assays.

"Greg brings considerable industry expertise to our operating team," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "His track record of developing and growing platform technologies, including Roche's highly successful PCR products, will help us navigate licensing and production of exosome non-invasive oncology assay."

Mr. Zdechlik, an in-vitro diagnostic industry veteran, has been with Roche Diagnostics for over 22 years, including 15 years in the clinical molecular diagnostics field. He served as a founding commercial team member of Roche Diagnostic's U.S. clinical molecular diagnostics group and has held executive level positions including sales management, corporate development and strategic marketing. His responsibilities included leading the effort to seek new technologies, evaluating new business opportunities for the U.S. diagnostic business, developing strategic investment and action plans to achieve U.S. market leadership for key Roche business platforms, directing efforts to ensure that clinical endpoints, clinical trial design, publication strategy, market development strategy, key opinion leader development and health economic strategy for high value technologies were aligned with the market needs to achieve peak product sales faster.

"This is one of the more exciting technologies I have seen in molecular diagnostics," said Zdechlik. "Exosome's technology has the potential to enable a series of companion and tumor profiling diagnostics which deliver valuable information for clinicians to precisely monitor cancer status and manage available therapies."

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary molecular diagnostic tests with applications in oncology and metabolic disease. The company's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers that can be reliably harvested from blood and urine and used diagnostically. For more information, visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exosome Diagnostics Announces Additions to Management Team
2. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
3. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
9. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
10. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... ... United States Patent and Trademark Office for its Patent Applications 14/858,857 and 13/669,785 ... allowances of these patent applications further expand the protection of G-CON’s R&D investments ...
(Date:7/17/2017)... ... July 17, 2017 , ... Whitehouse Laboratories is ... to encompass the full series of ISO 80369 standard test procedures. The ISO ... device and drug delivery systems. With this recent expansion, Whitehouse Labs becomes one ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders ... range of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has ... research and testing. , However, designing a custom panel for disease research ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... analytical instruments announced the launch of its new line of Rocking and Waving ... and waving shaker models (both analog and digital) for laboratory applications in a ...
Breaking Biology Technology:
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):